New drug duo aims to slow aggressive breast cancer
NCT ID NCT07413601
First seen Feb 17, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study tests whether adding a new drug (QL1706) to standard chemotherapy helps people with advanced triple-negative breast cancer live longer without their disease getting worse. About 78 adults who have already tried one or two prior treatments will be randomly assigned to get either the combo or chemo alone. The main goal is to see if the combo delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 17 Panjiayuan Nan Li, Chaoyang District, Beijing
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.